|Bid||305.79 x 800|
|Ask||310.00 x 1200|
|Day's Range||305.25 - 319.15|
|52 Week Range||196.78 - 404.20|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||72.99|
|Earnings Date||Jan 27, 2021 - Feb 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||294.07|
The genomic-sequencing leader is recovering more quickly from the COVID-19 pandemic than it anticipated.
Participating for Illumina today will be Francis deSouza, President and Chief Executive Officer; and Sam Samad, Chief Financial Officer. To better understand the risks and uncertainties that could cause actual results to differ, we refer you to documents that Illumina files with the Securities and Exchange Commission, including Illumina's most recent forms 10-Q and 10-K.
Illumina (ILMN) delivered earnings and revenue surprises of 32.47% and 10.15%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?